| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | -0.16 | 0.4 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.04 | 0.4 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.036 | 0.4 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.042 | 0.4 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | 0.042 | 0.4 |
| mRNA | blebbistatin | CTRPv2 | pan-cancer | AAC | -0.072 | 0.4 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | Irinotecan | FIMM | pan-cancer | AAC | 0.11 | 0.4 |
| mRNA | Mitomycin-C | GDSC1000 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.048 | 0.4 |